Predictive factors for response to treatment in patients with advanced renal cell carcinoma

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2443-2449

  López, Carolina Muriel ^a   Esteban, Emilio ^a   Astudillo, Aurora ^a   Pardo, Pablo ^a   Berros, Jose Pablo ^a   Izquierdo, Marta ^a   Crespo, Guillermo ^a   Fonseca, Paula J ^a   Sanmamed, Miguel ^a   Martínez Camblor, Pablo ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Advanced renal cell carcinoma; Cytokines; Molecular markers; New targeted drugs; Predictive factors of treatment response

Indexed keywords

CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P21; SORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPHILIA; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTOSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOKINES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; LEUKOCYTE DISORDERS; MIDDLE AGED; PROGNOSIS; PTEN PHOSPHOHYDROLASE; THROMBOCYTOSIS;

EID: 84875511102     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9836-4     Document Type: Review

References (43)

1. Godley PA, Ataga KI (2000) Renal cell carcinoma. Curr Opin Oncol 12:260-264
2. Jemal A, Murria T, Ward E, Samuels A, Tiwari RC (2005) Cancer statistics. Cancer J Clin 55:10-30
3. McLaughlin JK, Lipworth L (2000) Epidemiologic aspects of renal cell cancer. Semin Oncol 27:115-123
4. Greenlee RT, Murray T, Bolden S et al (2000) Cancer statistics Cancer J Clin 50.
5. Vinels P, Alavanja M, Buffer P et al (2004) Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 96:99-106
6. Maclurem WW (1990) A case control study of diet and risk of renal adenocarcinoma. Epidemiology 1:430
7. Hunt JD, van der Hel OL, McMillan GP et al (2005) Renal cell carcinoma en relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 114:101-108
8. Bergstrom A, Hsich CC, Lindbland P et al (2001) Obesity and renal cell cancer: a quantitative review. Br J Cancer 85:984-990
9. Bergstrom A, Pisani P, Tenet V et al (2001) Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91:421-430
10. Calle EE, Kaasks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591
11. Wolchok JD, Motzer RJ (2000) Management of renal cell carcinoma. Oncology 14:29-34
12. Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353:14-17
13. Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127-3132
14. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
15. Escudier B, Szezylik C, Eisen T et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
16. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281
17. Escudier BJ, Bellmunt J, Negrier S et al (2009) Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV)+interferon-α2a (IFN) in meta-static renal cell carcinoma (mRCC). J Clin Oncol 27:15s (suppl; abstr 5020)
18. Motzer RJ, Escudier B, Oudard S, RECORD-1. Study Group et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449-456
19. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061-1068
20. Bui MH, Seligson D, Han KR et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9:802-811
21. Hager M, Haufe H, Kemmerling R et al (2007) PTEN expression in renal cell carcinoma and oncocytoma and prognosis. Pathology 39:482-485
22. Bozhurt SU, Avan E, Bolukbasi F et al (2009) Immunohistochem-ical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS 117(9):651-659
23. Zoblec I, Steele R, Terracciano L et al (2007) Selecting immuno-histochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 60(10):1112-1116
24. Youden WJ (1950) Index for rating diagnostic tests. Cancer 3 (1):32-35
25. Miller AB, Hooqstraten B, Staquet M et al (1958) Reporting results of cancer treatment. Cancer 47:207-214
26. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481
27. Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic factors stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530-2540
28. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:286-296
29. Mekhail TM, Abou-Jawde RM, BouMerhi G et al (2005) Validation and extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23:832-841
30. Unruh A, Ressel A, Mohamed HG et al (2003) The hypoxia-inducible factor-1 is a negative factor for tumor therapy. Oncogene 22:3213-3220
31. Brugarolas J (2007) Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 356:185-187
32. Patel PH, Chadalavada RS, Ishill NM et al (2008) Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 26 (abstr. 5008)
33. Bui MH, Seligson D, Han KR et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9:802-811
34. Patard J-J, Fergelot P, Karakiewicz PI et al (2008) Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Carncer 123:395-400
35. Atkins M, Regan M, McDermott D et al (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714-3721
36. Klatte T, Zomorodian N, Kabbinavar FF et al (2007) Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma. J Clin Oncol 25 (abstr. 5112)
37. Signoretti S, Regan M, Atkins M (2008) Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. BJU Int 101(Suppl 4):31-35
38. Choueiri TK, Regan MM, Brick AJ et al (2008) Carbonic anhydrase IX (CAIX) and pathologic features as predictors of outcome in patients with metastatic renal cell carcinoma receiving VEGF-targeted therapy. ASCO Annual Meeting J Clin Oncol 26(Suppl 20):16042
39. Choueiri TK, Vaziri SA, Rini I et al (2007) Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25:5012
40. Fan Y, Borowsky AD, Weiss RH (2003) An antisense oligodeox-ynucleotide to p21 (Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther 2:773
41. Weiss RH (2003) p21 Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4:425
42. Hollen CW, Henthorn J, Koziol JA et al (1992) Serum interleukin-6 levels in patients with thrombocytosis. Leuk Lymphoma 8:235-241
43. Donskov F, Von der Maase H (2006) Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24:1997-2005